Celgene buys Juno for $9bn

Confirming rumors that began swirling a week prior, Celgene Corp. announced that it signed a definitive agreement to acquire the remaining 90.3% of cellular immunotherapies developer Juno Therapeutics Inc. that it didn’t already own for $87 per share or roughly $9bn. The share price represents an 80% premium to Juno’s trading average for the ten days prior to the January 17 media speculation.